4.8 Article

A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases

Journal

NATURE COMMUNICATIONS
Volume 13, Issue 1, Pages -

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41467-022-34521-0

Keywords

-

Funding

  1. Japan Agency for Medical Research and Development (AMED) [JP21wm0125002]
  2. JSPS KAKENHI [18K07141, 21K07038]
  3. National Institutes of Allergy and Infectious Diseases [HHSN272201400008C]
  4. Center for Research on Influenza Pathogenesis and Transmission [75N93021C00014]
  5. MUFJ-FG Vaccine Development Support Project [215100000358]

Ask authors/readers for more resources

In this study, researchers isolate a human monoclonal antibody that can bind to the neuraminidase of various subtypes of influenza viruses, providing broad protection in vitro and in vivo.
Improved vaccines and antiviral agents that provide better, broader protection against seasonal and emerging influenza viruses are needed. The viral surface glycoprotein hemagglutinin (HA) is a primary target for the development of universal influenza vaccines and therapeutic antibodies. The other major surface antigen, neuraminidase (NA), has been less well studied as a potential target and fewer broadly reactive anti-NA antibodies have been identified. In this study, we isolate three human monoclonal antibodies that recognize NA from A/H1N1 subtypes, and find that one of them, clone DA03E17, binds to the NA of A/H3N2, A/H5N1, A/H7N9, B/Ancestral-lineage, B/Yamagata-lineage, and B/Victoria-lineage viruses. DA03E17 inhibits the neuraminidase activity by direct binding to the enzyme active site, and provides in vitro and in vivo protection against infection with several types of influenza virus. This clone could, therefore, be useful as a broadly protective therapeutic agent. Moreover, the neutralizing epitope of DA03E17 could be useful in the development of an NA-based universal influenza vaccine. Broadly protective antibodies targeting influenza viruses are of interest as potential therapeutics or to inform vaccine development. Here the authors characterize a human mAb (DA03E17) with heterosubtypic binding to neuraminidases from IAVs and IBVs that provides broad protection in vitro and in vivo.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available